Breaking News
January 22, 2019 - Better mouse model built to enable precision-medicine research for Alzheimer’s
January 22, 2019 - Molecular profiling of precancerous lung lesions could lead to early detection and new treatments
January 22, 2019 - Genetic factors influence where fat is stored in our bodies
January 22, 2019 - The Psychology Behind Sticking to Your New Year’s Resolutions
January 22, 2019 - Scientists aim to find genetic causes of developmental abnormalities in the vagina and uterus
January 22, 2019 - Looming Global Crisis Means People’s Diets Must Change: Experts
January 22, 2019 - Excessive social media use is comparable to drug addiction
January 22, 2019 - Researchers show how mechanical stress affects bone development
January 22, 2019 - Study takes a step closer to understanding the body’s response to opioid painkillers
January 22, 2019 - Unexpected connection found between feeding and memory centers of the brain
January 22, 2019 - A revolutionary approach transforms bone trauma treatment
January 22, 2019 - Early studies and recent clinical trials on nerve growth factor
January 22, 2019 - Dry Mouth and Older Adults: Information for Caregivers
January 22, 2019 - Are your grandparents getting tipsy at the holiday party?
January 22, 2019 - New machine learning algorithms identify early symptoms of urinary tract infections
January 22, 2019 - Young women skipping the Pap smear test due to embarrassment
January 22, 2019 - A global influenza pandemic high on the WHO’s agenda
January 22, 2019 - Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
January 22, 2019 - Elastronics—hydrogel-based microelectronics for localized low-voltage neuromodulation
January 22, 2019 - Branched-chain amino acids in tumors can be targeted to prevent and treat cancer
January 22, 2019 - Fueling macrophages with energy to attack and eat cancer cells
January 22, 2019 - Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For Evenity (romosozumab)
January 22, 2019 - Does being bilingual make children more focused? Study says no
January 22, 2019 - Study reveals new genes and biological pathways linked to osteoarthritis
January 22, 2019 - FSU study provides better understanding of spinal cord injuries
January 22, 2019 - Delaying bath for newborn babies increases breastfeeding rates, finds study
January 21, 2019 - WHO identifies non-communicable diseases as major threat to human health
January 21, 2019 - Many parents still try non-evidence-based cold prevention methods for children
January 21, 2019 - High Levels of Activity, Motor Ability Linked to Better Cognition
January 21, 2019 - Killer blows? Knockout study of pair of mouse MicroRNA provides cancer insight
January 21, 2019 - Buffalo researchers receive grant to quicken development of generic equivalents of contraceptives
January 21, 2019 - One-third of pregnant women do not believe cannabis is harmful to their fetus
January 21, 2019 - Fiderstat could be used as chemopreventative drug for intestinal cancers caused by APC gene mutations
January 21, 2019 - Modifying healthcare delivery practices may improve discussions between youth and healthcare providers
January 21, 2019 - UNIST researcher named as recipient of Merck’s 2018 Life Science Awards
January 21, 2019 - How Getting a Flu Shot Could Save Your Life
January 21, 2019 - Surgical adhesions can be treated, prevented in mice
January 21, 2019 - Increased physician-targeted marketing associated with higher opioid overdose deaths
January 21, 2019 - Researchers uncover specific microbial signatures of intestinal disease
January 21, 2019 - Researchers discover new blood vessel system in bones
January 21, 2019 - Simple blood test reliably detects signs of Alzheimer’s damage before symptoms
January 21, 2019 - Study to investigate new targeted oral treatments for severe asthma
January 21, 2019 - Plan Your Plate | NIH News in Health
January 21, 2019 - Fecal occult blood test may improve CRC outcomes in some
January 21, 2019 - Blood test detects Alzheimer’s disease years before symptoms develop
January 21, 2019 - Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS
January 21, 2019 - FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
January 21, 2019 - The causes and complications of snoring
January 21, 2019 - Placenta adapts and compensates when pregnant mothers have poor diets or low oxygen
January 21, 2019 - New implant could restore the transmission of electrical signals in injured central nervous system
January 21, 2019 - Rapid-acting fentanyl test strips found to be effective at reducing overdose risk
January 21, 2019 - Coronary Artery Calcium May Help Predict CVD in South Asians
January 21, 2019 - The mystery of the super-ager
January 21, 2019 - Scientists develop smart microrobots that can change shape depending on their surroundings
January 21, 2019 - Keep Moving to Keep Brain Sharp in Old Age
January 21, 2019 - Despite progress, gay fathers and their children still structurally stigmatized
January 21, 2019 - New drug for treating liver parasites in vivax malaria
January 21, 2019 - Merck recognized with 2018 Life Science Industry Award for best use of social media
January 21, 2019 - Coeur Wallis equips the canton of Valais with 260 SCHILLER defibrillators
January 21, 2019 - Scientists propose quick and pain-free method for diagnosing kidney cancer
January 21, 2019 - Signs of memory loss could point to hearing issues
January 21, 2019 - HeartFlow Analysis shows highest diagnostic performance for detecting coronary artery disease
January 21, 2019 - How Much Caffeine is Too Much?
January 21, 2019 - Take a timeout before you force your child to apologize
January 21, 2019 - Scientists design two AI algorithms to improve early detection of cognitive impairment
January 21, 2019 - Novel therapy for children with chronic hormone deficiency provides lifeline for parents
January 21, 2019 - Bioethicists call for oversight of poorly regulated, consumer-grade neurotechnology products
January 21, 2019 - Study shows hereditary hemochromatosis behind many cancers and joint diseases
January 21, 2019 - Short bouts of stairclimbing throughout the day can improve cardiovascular health
January 20, 2019 - Liver Transplant Survival May Improve With Race Matching
January 20, 2019 - Study implicates hyperactive immune system in aging brain disorders
January 20, 2019 - Cancer Diagnosis May Quadruple Suicide Risk
January 20, 2019 - Parkinson’s disease experts devise a roadmap
January 20, 2019 - Research brings new hope to treating degenerative brain diseases
January 20, 2019 - Scientists pinpoint a set of molecules that wire the body weight center of the brain
January 20, 2019 - Researchers get close to developing elusive blood test for Alzheimer’s disease
January 20, 2019 - UCLA researchers demonstrate new technique to develop cancer-fighting T cells
January 20, 2019 - Researchers discover how cancer cells avoid genetic meltdown
January 20, 2019 - Exercise makes even the ‘still overweight’ healthier: study
January 20, 2019 - University of Utah to establish first-of-its-kind dark sky studies minor in the US
Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam reports further progress on broadening the therapeutic potential of RNAi

image_pdfDownload PDFimage_print

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today further progress on the Company’s platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs). Preclinical results were presented at the Oligonucleotide Therapeutics Society (OTS) 2018 Annual Meeting held September 30 to October 3 in Seattle, WA.

“We are pleased to report on our continued progress on broadening the therapeutic potential of RNAi by demonstrating successful delivery to extrahepatic tissues such as the CNS and eye. The in vivo activity of our novel CNS and ocular siRNA conjugates is consistent across species and targets with potent and highly durable mRNA silencing. As we have seen with liver target gene silencing, we anticipate a highly competitive profile for our siRNA conjugates with increased potency, extended duration of action, and encouraging safety margins,” said Kevin Fitzgerald, Ph.D., Senior Vice President, Research at Alnylam. “We are excited to grow the potential universe of tissues, targets, and diseases addressable by RNAi therapeutics, expanding our efforts to reach patients in need of new therapies. We believe that the demonstration of potent, safe, and infrequent dosing may allow us to develop innovative RNAi therapeutics directed to these new targets.”

In NHP studies, a single intrathecal (IT) injection of a siRNA conjugate targeting the ubiquitously expressed β-catenin mRNA transcript resulted in broadly distributed target gene silencing across the brain and spinal cord. Robust and durable silencing of β-catenin mRNA was observed after a single dose at day 31 post injection. Specifically, a single 72 mg dose (approximately 24 mg/kg) resulted in over 80 percent target silencing in the spinal cord and approximately 50 percent silencing across regions of the brain. Widespread distribution of the novel siRNA conjugate was observed across the CNS, including the frontal and temporal cortex, deep brain structures such as basal ganglia and dentate gyrus, cerebellum, brain stem and spinal cord, with evidence for cellular localization in neurons, astrocytes, and microglia. In additional rat studies, further optimization of novel conjugates was reported using siRNAs targeting superoxide dismutase 1 (SOD1), a genetically defined disease gene implicated in amyotrophic lateral sclerosis (ALS). Additional optimization of the conjugate design resulted in an over ten-fold improvement in potency, with a dose as low as 0.07 mg (approximately 0.25 mg/kg) resulting in approximately 50 percent SOD1 silencing across the CNS. In both rat and NHP studies, intrathecal administration of these novel siRNA conjugates was found to be generally well tolerated. Consistent with previous guidance, Alnylam expects to select its first CNS Development Candidate (DC) by the end of 2018 with an initial Investigational New Drug (IND) or equivalent application in late 2019 or early 2020.

Alnylam scientists also presented new preclinical results with novel siRNA conjugates targeting transthyretin (TTR), demonstrating delivery to ocular tissue in rats and NHPs. Efficient and durable silencing of ocular TTR mRNA in rat was achieved following a single intravitreal injection, with siRNAs localizing to the relevant cell types in the eye, retinal pigment epithelium (RPE) and ciliary epithelia (CE), where amyloid deposits can occur in approximately 10 percent of hereditary ATTR (hATTR) amyloidosis patients. The ocular target gene silencing effect was recapitulated in NHPs with approximately 98 percent silencing of TTR mRNA in RPE and near complete knockdown of TTR protein at day 31, as measured in immunohistochemical analyses. In NHP studies, there were no notable safety findings related to administration of ocular siRNA conjugates.

Additional OTS presentations by Alnylam scientists and collaborators included results on:

  • Further optimization of the Company’s enhanced stabilization chemistry plus (ESC+) conjugate platform
  • Safety evaluation of 2′-Fluoro-modified nucleotides embedded in GalNAc-conjugate siRNAs
  • Simultaneous silencing of two different gene transcripts with Bis-RNAi conjugates.

For the full breadth of results presented by the Company at OTS please visit the Capella section of the Alnylam website.

We are also pleased to share that Alnylam’s publication of results from the APOLLO Phase 3 pivotal trial of patisiran featured in the July 5, 2018 issue of The New England Journal of Medicine has been selected as the OTS “2018 Paper of the Year” – an award designed to honor the year’s most impactful paper in the field of oligonucleotide therapeutics.


Tagged with:

About author

Related Articles